Take our Dementia Test

Find a therapist to help with dementia

Dementia is a common late-life disease with few treatments and devastating consequences.

There are two distinct approaches to dementia: prevention and treating established disease.

Current evidence is equivocal regarding treatment but stronger for prevention.

Sandra spends most Tuesday afternoons in a neurologist's waiting room, scrolling on her phone while her mother finishes a cognitive assessment down the hall. Her mother was diagnosed with Alzheimer's disease two years ago, and Sandra has spent those two years learning a hard truth: unlike most of the health crises she has faced in her family, this one comes with few good treatment options and a daunting road ahead.

Sandra is 52. Alzheimer's runs in her family, and she has started to wonder, privately in years past and then more overtly during the past two years, what her own future holds.

Like millions of people struggling with a parent's dementia diagnosis, Sandra has seen the headlines. GLP-1 medicines, the same drugs reshaping conversations about weight and diabetes, are now being discussed as a possible treatment for Alzheimer's disease. She brought the question to her mother's neurologist, Dr. Reyes, hoping for a reason to be optimistic.

Dr. Reyes was careful. The evidence, she explained, is not yet strong enough to recommend a GLP-1 medicine as a treatment for Sandra's mother. The research is real, but premature, and the results so far have been mixed.

Then Dr. Reyes said something Sandra didn't expect. Given Sandra's family history, and that Sandra had already been considering a GLP-1 medicine for other conditions, the more promising conversation was not about treating her mother's disease, but about possibly lowering her own risk.

That distinction, between treating dementia and preventing it, turns out to be the most important thing to understand about this fast-moving area of research.

Why Treatment Remains Uncertain

The excitement about GLP-1 medicines and Alzheimer's disease is substantial, but so is the uncertainty. In late 2025, the two largest clinical trials ever conducted on a GLP-1 medicine and Alzheimer's, testing semaglutide in people who already had mild cognitive impairment, failed to show that the drug slowed the disease's progression.1 Around the same time, a separate and smaller trial of a related medicine,........

© Psychology Today